Cargando…
Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis
BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) is a growing public health burden, with mortality and rehospitalization rates comparable to HF with reduced ejection fraction (HFrEF). The evidence for the clinical usefulness of soluble suppression of tumorigenicity 2 (sST2) in...
Autores principales: | Shi, Yujiao, Liu, Jiangang, Liu, Chunqiu, Shuang, Xiong, Yang, Chenguang, Qiao, Wenbo, Dong, Guoju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530661/ https://www.ncbi.nlm.nih.gov/pubmed/36204571 http://dx.doi.org/10.3389/fcvm.2022.937291 |
Ejemplares similares
-
Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
por: Shi, Yujiao, et al.
Publicado: (2022) -
A rat model of metabolic syndrome-related heart failure with preserved ejection fraction phenotype: pathological alterations and possible molecular mechanisms
por: Shi, Yujiao, et al.
Publicado: (2023) -
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
Publicado: (2017) -
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: AbouEzzeddine, Omar F., et al.
Publicado: (2017) -
Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)